When cancer leaves only molecular traces, RaDaR ST brings them into view.
MRD detection, personalized to every patient’s tumor
RaDaR ST analyzes each patient's unique tumor profile to develop a personalized panel—then uses that panel to detect the presence or absence of circulating tumor DNA in the patient's bloodstream.
Why choose RaDaR ST for MRD testing?
RaDaR ST provides clear, actionable answers at every major decision point—from adjuvant treatment through long-term surveillance—helping you manage patients with confidence.
 | RaDaR ST detects trace amounts of circulating tumor DNA. |
 | RaDaR ST detects ctDNA and evidence of molecular recurrence, enabling earlier intervention and personalized treatment decisions. |
 | Proven performance built for confident decision-making, and detection as low as 1 ppm.* |
 | RaDaR ST delivers intuitive, easy-to-interpret reports that translate complex molecular data into clear clinical guidance. |
Delivering clinical confidence across the entire care continuum
Built for confident decision-making, RaDaR ST offers proven analytical performance with specificity of nearly 100%, detection as low as 1 ppm1. Its ability to detect extremely low levels of circulating tumor DNA enables early, reliable identification of molecular residual disease or recurrence, minimizing false positives and supporting timely care decisions.
RaDaR ST is supported by a growing foundation of clinical and real-world data demonstrating its powerful performance, reliability, and impact across solid tumors. Peer-reviewed studies and multi-center validations show that RaDaR ST consistently correlates MRD status with recurrence risk, treatment response, and patient outcomes—giving you evidence-backed confidence in every result.
Seamless ordering workflows for every practice
Intuitive ordering that fits seamlessly into your clinic’s daily workflow.
From simplified requisitions, online ordering, and flexible sample collection options to personalized assistance for onboarding, troubleshooting, and result interpretation. Minimize administrative burden and ensure your practice always has the support it needs.
Delivering clear and actionable answers with RaDaR ST.
Coverage that counts. Access that matters. Over 300 in-network commercial insurance contracts.
RaDaR ST is Medicare-approved for select solid tumor indications. This coverage helps ensure more patients can benefit from MRD-guided insights while giving your practice greater certainty and smoother billing workflows.
References
NeoGenomics data on file. Sensitivity demonstrated across four independent analytical and clinical validation studies, with detection of LOD95 at 11 parts per million (ppm) and under certain study-specific conditions, as low as 1 ppm. (Cabel L, et al. https://pubmed.ncbi.nlm.nih.gov/41611726/, Elliott MJ et al. https://pubmed.ncbi.nlm.nih.gov/39984446/, Stanciu A et al. https://pubmed.ncbi.nlm.nih.gov/41350280/, Schuurbiers MMF et al. https://pubmed.ncbi.nlm.nih.gov/40233104/), Elliott MJ, Echelard P, Pipinikas C, et al. Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assay. Nat Commun. 2025;16(1):1837. Published 2025 Feb 21. doi:10.1038/s41467-025-56658-4, Flach, S., Pipinikas, C., Huberty, T. et al. Personalized ctDNA analysis for detection of residual disease and recurrence in surgically treated HNSCC patients. npj Precis. Onc. 10, 103 (2026), Flach S, Howarth K, Hackinger S, et al. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer. 2022;126(8):1186-1195. doi:10.1038/s41416-022-01716-7
RaDaR ST for Breast Cancer
Address HR+/HER2- breast cancer long-term recurrence risk months before conventional methods
Hormone receptor (HR+) positive/HER2 negative tumors represent nearly 70% of breast cancer diagnoses and pose a unique clinical challenge. Unlike other breast cancer subtypes, late recurrences are common in patients with HR+/HER2- tumors, with over half of metastatic recurrences occurring 5+ years post-initial diagnosis. The risk of recurrence remains high for these patients for at least 20 years after curative intent treatment. This creates a significant unmet need, as current methods cannot detect breast cancer recurrence until tumors present on scans—missing the critical intervention window when disease burden is minimal and treatment is most likely to succeed.
RaDaR ST provides over a year's advance warning of distant metastasis, opening the door to life-changing interventions.
The test detects early evidence of recurrence, well before the tumor becomes metastatic, detecting 100% of distant metastatic recurrences in a 3.9-year study of 83 patients, with a remarkable median lead time of 12.4 months before clinical detection—providing an unprecedented window to intervene when disease burden is minimal and treatment may be most effective.1 For high-risk HR+/HER2- early-stage breast cancer patients, RaDaR ST extends vigilance beyond the early years to the long-term survival window by enabling continuous molecular surveillance in the late adjuvant setting, addressing the persistent threat of late recurrence that imaging alone may miss until it's too late.
Additionally, when endocrine-responsive biomarkers indicate high recurrence risk despite anti-estrogen therapy, integrating RaDaR ST testing can refine treatment decisions by detecting and monitoring circulating tumor DNA for more comprehensive risk assessment.
Breast cancer care continuum
From diagnosis through surveillance: delivering timely, actionable insights so that every treatment decision is as personal as the patients themselves.
How RaDaR ST impacts the cancer care continuum
Case Study: Early detection changes the paradigm
A 52-year-old woman, diagnosed with Stage II ER+/PR+/HER2- breast cancer, completed her treatment successfully and showed no evidence of disease for 7 years. Then, during a routine 7-year surveillance, RaDaR ST detected ctDNA in her blood, even though imaging showed nothing unusual.
Her care team responded by scheduling more frequent monitoring, and 3 months later, the intensified imaging found a single bone lesion. She was quickly treated with targeted, local radiation and systemic therapy. The ctDNA cleared, and 18 months later, the patient remains on therapy with no signs of progression.*
*Data on file
Case study: Recurrence monitoring provides early warning
When a 52-year-old woman noticed swelling, pain, and itchiness in her left breast, her family physician ordered imaging that revealed resectable stage III breast cancer with 3 involved lymph nodes, but no distant metastases. Given her high risk for recurrence, she underwent a mastectomy to remove the primary tumor and affected lymph nodes, followed by 12 weeks of adjuvant chemotherapy and 5 years of endocrine therapy. But 6 years after completing her adjuvant therapy, RaDaR ST detected ctDNA in her blood. A breast MRI came back negative, but her clinical team increased examination frequency to every three months. It took 12 months for imaging to confirm that the cancer had returned, confirming what RaDaR ST had signaled a year earlier.
*Data on file
References
Lipsyc-Sharf M, de Bruin EC, Santos K, et al. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2022;40(22):2408-2419. doi:10.1200/JCO.22.00908
RaDaR ST for Head & Neck Cancer
Closing the Surveillance Gap in HPV-Negative Head & Neck Cancer
HPV-negative head and neck squamous cell carcinoma (HNSCC) presents a significant clinical challenge, with many patients developing disease recurrence and fewer than 50% surviving beyond five years. HPV-negative patients face worse outcomes compared to their HPV-positive counterparts, and unlike HPV-positive disease, reliable biomarkers for therapy planning and monitoring treatment response do not exist for this population.
Current head and neck cancer adjuvant therapy monitoring and surveillance cannot answer two critical questions:
- Did surgery remove all the cancer?
- Are there ways to identify disease before clinical or radiographic signs appear?
This gap in monitoring leaves clinicians and patients without the tools needed to detect recurrence early when intervention may be most effective.
Earlier detection to support salvage treatment success
RaDaR ST delivers unprecedented sensitivity in detecting HPV-negative HNSCC recurrence, achieving 100% detection of relapsed patients by identifying ctDNA at ultra-low levels of 5ppm—ensuring no patient with recurrent disease goes undetected during the critical surveillance window.
Post-surgical ctDNA monitoring identifies disease relapse a median of 154 days (over 5 months) before clinical confirmation, providing crucial lead time when salvage surgery and radiation are most likely to succeed and before symptoms impact quality of life.
This sensitivity advantage is essential, as nearly one-third of positive samples had variant allele frequencies below 0.01%. It demonstrates standard sensitivity assays may miss a significant proportion of HNSCC relapse leaving patients to present with more advance disease.
Head and neck cancer care continuum
From diagnosis through surveillance: delivering timely, actionable insights so that every treatment decision is as personal as the patients themselves.
Case study: When salvage treatment success rates are highest
When a 60-year-old man noticed a growing lump on his neck, he went to his doctor for evaluation. His medical history included 30 years of smoking and alcohol use, and his physical examination revealed a large, firm mass on the left side. A subsequent biopsy confirmed p16-negative squamous cell carcinoma. Imaging showed the cancer was still localized, and he underwent surgery to remove the mass.
Four weeks post-surgery, despite clear resection margins, RaDaR ST testing detected ctDNA in his blood. Additional surgery was performed within days, and his postoperative ctDNA levels dropped to undetectable. The patient continued regular monitoring with both imaging and RaDaR ST every 3 months. The patient's ctDNA appeared 9 months after surgery but imaging did not detect it until 6 months after RaDaR ST. The residual disease was identified by RaDaR ST months before imaging.*
*Data on file
References
Flach S, Howarth K, Hackinger S, et al. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br J Cancer. 2022;126(8):1186-1195. doi:10.1038/s41416-022-01716-7
RaDaR® ST—Immunotherapy response monitoring
When imaging alone doesn’t tell the whole story
Assessing response to immunotherapy can be challenging. Pseudoprogression, delayed response, and mixed response may make conventional imaging difficult to interpret and complicate clinical decision-making. However, patients may derive meaningful clinical benefit from immunotherapy despite delayed, mixed, or perceived radiographic progression.1
RaDaR ST provides a personalized molecular view of ctDNA dynamics over time, helping characterize immunotherapy response alongside imaging and clinical evaluation.1,2,3
Order RaDaR ST for Immunotherapy response monitoringDownload the Immunotherapy brochure
From imaging uncertainty to molecular insight
Changes in ctDNA may provide insight into treatment response before those changes are visible through imaging.1,2,3
Early ctDNA decrease or clearance has been associated with improved disease-free survival, progression-free survival, and overall survival compared with no molecular response1,2,3
Serial ctDNA monitoring provides an additional molecular view of treatment response and disease dynamics over time. Interpret results alongside imaging, clinical evaluation, and other relevant patient information.1,2,3
What longitudinal ctDNA monitoring may reveal
Across multiple studies, ctDNA clearance and decreasing ctDNA identified patients benefiting from immunotherapy, while persistent or increasing ctDNA provided an early indication of limited molecular response.1,2,3
Molecular response assessment with RaDaR ST across immunotherapy settings
Serial molecular monitoring with RaDaR ST may help distinguish patients experiencing treatment benefit from those with persistent or progressive molecular disease. RaDaR ST has demonstrated clinical performance in immunotherapy response monitoring across the continuum of cancer care.1,2,3
Neoadjuvant immunotherapy
In the NABUCCO study of patients with stage III muscle-invasive bladder cancer receiving neoadjuvant immunotherapy:
Patients who achieved ctDNA clearance after neoadjuvant immunotherapy and before surgery demonstrated approximately 45-fold greater odds of achieving a pathologic complete response.
ctDNA clearance was strongly associated with improved progression-free survival and overall survival.1
Adjuvant immunotherapy
In the OXEL study of patients with residual TNBC following neoadjuvant therapy and treated with adjuvant nivolumab and/or capecitabine, ctDNA identified patients at greatest risk and led to worse clinical outcomes.
Postoperative ctDNA positivity identified patients at greatest risk of recurrence.
Patients who were ctDNA-positive at landmark assessment had inferior median invasive disease-free survival compared with patients who were ctDNA-negative.
All ctDNA-positive patients who failed to clear ctDNA by week 6 experienced recurrence. 2
Advanced or metastatic disease
In the Ruiz-Torres et al. study, patients with recurrent or metastatic head and neck squamous cell carcinoma receiving immunotherapy, ctDNA dynamics were strongly associated with disease control and clinical outcomes:
Patients who achieved ctDNA clearance during treatment had approximately 22-fold greater odds of disease control.
ctDNA clearance during immunotherapy treatment was associated with a 97% lower risk of disease progression (HR 0.03, P=0.006) and a 96% lower risk of death (HR 0.04, P=0.003).³
RaDaR ST is not intended to replace imaging or clinical evaluation. It provides an additional, personalized molecular view that may help clinicians:
Characterize treatment response over time
Identify molecular response or progression earlier
Add context when imaging findings are uncertain
Better understand disease dynamics during immunotherapy
RaDaR ST results should be interpreted together with imaging, clinical evaluation, treatment history, and other relevant clinical information.
van Dorp J, Pipinikas C, Suelmann BBM, et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat Med. 2023;29(3):588-592. doi:10.1038/s41591-022-02199-y
Lynce F, Mainor C, Donahue RN, et al. Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study. Nat Commun. 2024;15(1):2691. Published 2024 Mar 27. doi:10.1038/s41467-024-46961-x
Ruiz-Torres DA, Merkin RD, Bryan M, et al. Personalized circulating tumor DNA dynamics predict survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer. Preprint. medRxiv. 2025;2025.01.27.25321198. Published 2025 Jan 28. doi:10.1101/2025.01.27.25321198